Interestingly, a meta-analysis of 51 histone methyltransferases in 958 breast cancer samples revealed that SET1A is amplified, while MLL3 is mutated the most in the Luminal A subtype, which highlights the significance of MLL3 and SET1A in ERα signaling [43]. Here, PRDM9 is linked to breast cancer.